Development and Validation of a Clinic Machine Learning Classifier for the Prediction of Risk Stratifications of Prostate Cancer Bone Metastasis Progression to Castration Resistance
Xin Li,Peng Cui,XingXing Zhao,Zhao Liu,YanXiang Qi,Bo Liu
DOI: https://doi.org/10.2147/ijgm.s465031
IF: 2.145
2024-06-22
International Journal of General Medicine
Abstract:Xin Li, 1, &ast Peng Cui, 1, &ast XingXing Zhao, 1 Zhao Liu, 1 YanXiang Qi, 1 Bo Liu 2 1 Department of Urology, Baotou Cancer Hospital, Baotou, Inner Mongolia, People's Republic of China; 2 Department of Gynaecological Oncology, Baotou Cancer Hospital, Baotou, Inner Mongolia, People's Republic of China &astThese authors contributed equally to this work Correspondence: Bo Liu, Email Objective: To explore the predictive factors and predictive model construction for the progression of prostate cancer bone metastasis to castration resistance. Methods: Clinical data of 286 patients diagnosed with prostate cancer with bone metastasis, initially treated with endocrine therapy, and progressing to metastatic castration resistant prostate cancer (mCRPC) were collected. By comparing the differences in various factors between different groups with fast and slow occurrence of castration-resistant prostate cancer (CRPC). Kaplan-Meier survival analysis and COX multivariate risk proportional regression model were used to compare the differences in the time to progression to CRPC in different groups. The COX multivariate risk proportional regression model was used to evaluate the impact of candidate factors on the time to progression to CRPC and establish a predictive model. The accuracy of the model was then tested using receiver operating characteristic (ROC) curves and decision curve analysis (DCA). Results: The median time for 286 mCRPC patients to progress to CRPC was 17 (9.5– 28.0) months. Multivariate analysis showed that the lowest value of PSA (PSA nadir), the time when PSA dropped to its lowest value (timePSA), and the number of BM, and LDH were independent risk factors for rapid progression to CRPC. Based on the four independent risk factors mentioned above, a prediction model was established, with the optimal prediction model being a random forest with area under curve (AUC) of 0.946[95% CI: 0.901– 0.991] and 0.927[95% CI: 0.864– 0.990] in the training and validation cohort, respectively. Conclusion: After endocrine therapy, the PSA nadir, timePSA, the number of BM, and LDH are the main risk factors for rapid progression to mCRPC in patients with prostate cancer bone metastases. Establishing a CRPC prediction model is helpful for early clinical intervention decision-making. Keywords: metastatic prostate cancer, resistance to castration, PSA minimum value, lactate dehydrogenase, prediction model Prostate cancer is the most common malignant tumor in elderly men and the second leading cause of cancer death in men worldwide, second only to lung cancer. 1,2 According to the global cancer statistics in 2022, the incidence of prostate cancer in the world in recent years has continued to grow, and has become an important disease burden for all countries in the world. 3 Localized prostate cancer often has a better prognosis after radical treatment, but epidemiological data shows that the vast majority of patients are already in the advanced stage of the disease at the time of treatment, experiencing bone metastasis and losing the opportunity for radical treatment. 4 Prostate cancer bone metastasis not only causes bone related symptoms such as bone pain, limited mobility, and increased risk of fractures but also leads to patients losing the opportunity for curative surgery. 5 Androgen deprivation therapy (ADT) is the gold standard for treating prostate cancer patients with bone metastases. 6 Although this endocrine therapy has a significant initial therapeutic effect on these patients, most patients inevitably progress to castration resistant prostate cancer (CRPC) after 1 to 2 years of treatment. 6,7 The survival time of patients who progress to CRPC is significantly shortened, and currently the treatment options for CRPC are limited. The effective time window for second-generation androgen drugs such as abiraterone and enzalutamide is only about 7 months. 8 Nowadays, the occurrence of CRPC is a challenging issue in the clinical diagnosis, treatment, and basic treatment of prostate cancer. There is a significant difference in the time it takes for different patients to develop CRPC after receiving ADT treatment in clinical practice, especially for prostate cancer patients who have significant individual differences. Therefore, exploring the speed at which prostate cancer patients with bone metastasis progress to CRPC can better indicate which patients will benefit from ADT treatment, while other patients may benefit more from chemotherapy, which has certain guiding significance for the clinical diagnosis and treatment of prostate cancer patients. -Abstract Truncated-
medicine, general & internal